|
|
|
|
|
|
|
|
|
|
| |
PHARMACEUTICAL CONTRACTING FY2005 |
|
| TRACKING |
|
| |
Contract Savings is calculated based on savings
over the price of the medication without the contract. It is not figured by savings over another
contract. |
|
| |
|
|
|
|
|
|
|
|
|
| CONTRACT |
|
REQUIREMENTS |
DURATION |
MUSC Medical
Center |
OUT-PT
PHARMACY |
Total |
Implementation Date |
Annualized Savings to Date |
|
| MEDICATION(S) |
Projected Annualized
Savings |
|
| IMPLEMENTED
CONTRACTS |
|
|
|
|
|
|
|
|
|
| Advanced Medical Optics - Healon |
Healon |
|
|
|
|
|
Aug-05 |
|
|
| Pfizer - Healon |
Healon |
95% MS |
|
|
|
|
Apr-04 |
Healon sold to another company before contract savings realized |
|
| Amgen DSH Program |
Aranesp, Neupogen, Neulasta |
Maintain a 50%
market share of Aranesp |
pricing may change qtrly with PHS price |
|
|
|
Jul-04 |
$351,000 |
|
| Anesthesia Portfolio |
various |
Purchase all products on the portfolio |
New program begins 7/1/05 |
|
|
|
|
$391,330 |
|
| Astra Zeneca Nexium Nominal pricing agreement |
Nexium |
|
|
|
|
|
|
$220,000 |
|
| Astra Zeneca Hospital Partnership Opportunity Program |
various |
All AZ products purchased by MUSC will receive a rebated based
on performance tier |
Jun-05 |
|
|
|
|
$16,292 |
expired |
| Astra Zeneca Merrem/Cefotan agreement |
Merrem and Cefotan |
Tiered discount based on performance |
until terminated |
|
|
|
|
$45,495 |
|
| Astra Zeneca Toprol DSH Agreement |
Toprol XL |
Inpatient and
outpatient DSH price |
Dec-05 |
|
|
|
|
$40,290 |
|
| Aventis |
Lovenox |
Tiered discount based on Markets share and gross sales volume |
until terminated |
|
|
|
|
$68,651 |
|
| Baxa Exacta-Mix Supplies |
Exacta-Mix Supplies |
|
May-09 |
|
|
|
Jul-04 |
$38,419 |
|
| B Brauhn Duplex |
Cefazolin Duplex Bags |
80% of all cefazolin purchases are duplex bags |
until terminated |
|
|
|
Jul-04 |
$326 |
|
| B Brauhn Trophamine |
Trophamine |
Discount is based on units purchased |
Mar-07 |
|
|
|
Jul-04 |
$6,763 |
|
| Bristol Myers Squibb - Tequin Contract |
|
|
|
|
|
|
Jul-04 |
$98,863 |
|
| Eli Lilly |
Zyprexa |
must purchase between $200k and $2M in 12 mo to receive 5%
discount |
5% off of NWP |
|
$4,000 |
|
Aug-04 |
$11,350 |
|
| Elan -
Maxipime LOC |
Maxipime |
Tiered discount based on maxipime market share (currently at
Tier 3) |
until terminated |
|
|
|
Jun-02 |
$41,777 |
|
| Fujisawa
Ambisome Pricing Program |
Ambisome |
Formulary preferred lipid ambisome product ($62.50 per vial) |
Sep-07 |
|
|
$179,000 |
Jan-05 |
$234,000 |
discontinued when DSH
program came available. |
| Fujisawa
Ambisome Pricing Program for DSH |
Ambisome |
Formulary preferred lipid ambisome product (52.50 per vial) |
Sep-07 |
|
|
$230,000 |
Jun-05 |
|
|
| GlaxoSmithKline
Acute Care Base Rebate Program |
Zofran, Imitrex, Fortaz, Advair, Flovent, Serevent, Coreg,
Arixtra, Engerix, Havrix, Infanrix, Boostrix, Pediarix, Twinrix, Paxil,
Wellbutrin, Augmentix XR, Avandia, Avodart, Argatroban. |
Various market share requirements for various market baskets |
until terminated |
|
|
|
|
166753 |
|
| GE Healthcare |
Optison |
|
Mar-08 |
|
|
|
Mar-05 |
|
not correctly loaded in
Mckesson |
| GE Healthcare |
Visipaque, Omnipaque, Omniscan, Hypaque |
Discount based on market share and total dollars spent |
|
|
|
|
|
|
|
| Hospira DSH SafetyNet Program |
various |
4.1% rebate for hospira products purchased by MUSC with
exclusions. Rebate check is annual
from anniversary date |
Sep-07 |
|
|
|
Apr-05 |
|
|
| Merck Plus 2 contract |
Primaxin/Invanz |
tiered discount
based on Market Share |
until
terminated |
|
|
|
|
$32,181 |
|
| Merck Vioxx Contract |
Vioxx |
|
TERMINATED |
|
|
|
|
|
|
| Merck SAVE program |
Zocor |
Do not meet 70% MS requirement - Rejected for Pfizer Lipitor
agreement |
|
|
|
|
|
|
|
| Merck Vaccine program |
various |
Recombivax/Comvax are the exclusive Hep B vaccines on Formulary |
until
terminated |
|
|
|
|
$15,717 |
|
| NovoNordisk Novlin/Novolog Disocount |
Novolin and
Novolog |
80% MS |
May-07 |
|
|
|
Oct-04 |
$34,049 |
|
| Oncology Portfolio |
various |
Purchase all products on the portfolio |
New program begins 7/1/05 |
|
|
|
|
$357,611 |
|
| Ortho McNeil Levaquin PDOT Preferred Pricing |
|
>90% MB; rebates 6% off all injectables |
|
|
|
REJECTED |
|
|
|
| Pfizer Celebrex Performance Agreement |
|
|
Discontinued |
|
|
|
|
|
|
| Pfizer Disproprtionate Share Hospital PHS Agreement |
Lipitor |
Must maintain a 70% market share of Lipitor in the PHS accts. |
Dec-05 |
|
|
|
Jan-05 |
$180,000 |
|
| Pfizer Fragmin Performance Participation |
Fragmin |
Discount based on market share (MUSC - <25%) |
until terminated |
|
|
$1,600.00 |
Dec-05 |
|
expecting credit rebills
from Mck |
| Pfizer Novation Acute Care Contract (Inpatient Only) |
various |
|
|
|
|
|
|
$178,700 |
|
| Roche Kytril Antiemetic Contract |
|
MS discount |
|
|
|
REJECTED |
|
|
|
| Roche
Transplant Program |
Cellcept, Zenapax, Valcyte, Cytovene IV |
Roche
transplant meds must be Formulary agent of choice, |
Dec-06 |
|
|
|
Jan-05 |
$214,447 |
|
| Ross
Nutrition Agreement |
Various
nutritionals |
tiered discount based on Market Share (and pumps but exception
was made for MUSC) |
Sep-07 |
|
|
|
|
$176,672.00 |
|
| Tap Prevacid nominal pricing agreement |
Prevacid |
nominal price for Prevacid for 340B eligible outpatient NON
RETAIL pharmacies |
1/1/2005 - 12/31/05 |
|
|
|
|
$120,000 |
|
| Wyeth Protonix Nominal Pricing Agreement |
|
|
|
|
|
|
|
$348,220.00 |
|
| Wyeth Zosyn Performance Rebate |
Zosyn |
tiered market share requirement (MUSC 10% rebate) |
until terminated |
$55,800 |
|
$55,800.00 |
Apr-05 |
$55,800 |
|
| |
|
|
|
|
|
|
|
|
|
| Non-Novation
Contracts |
|
|
|
|
|
|
|
|
|
| Rebate
program for Baxter products (75 days post Novation rollout) |
various |
convert to baxter brand upon Novation rollout |
12/15/2004 only for 75 days from October 1 |
$5,000 |
none |
$5,000.00 |
Oct-04 |
$6,175 |
|
| Repligen
SecreFlo Pricing Contract |
Secreflo |
Secreflo is our formulary secretin |
Jun-07 |
$12,000 |
|
$12,000.00 |
Aug-05 |
|
|
| Ross/Mead
Johnson Baby Formula Anciliary Items |
water, nipples,
volufeeders, glucose, ortho nipples |
During
Ross and MJ rotation, ancilliary items used from that manufacturer will be at
no charge |
until
terminated |
$75,000 |
|
$75,000.00 |
Jun-05 |
anticipated
in 2006 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$3,450,881 |
|
| |
|
|
|
|
|
|
|
|
|
| |
Items of Interest |
|
| |
|
|
|
|
|
|
|
|
|
| Item |
|
REQUIREMENTS |
DURATION |
MUSC Medical
Center |
OUT-PT
PHARMACY |
Total |
Implementation Date |
Annualized Savings to Date |
|
| MEDICATION(S) |
Projected Annualized
Savings |
|
| Availability
of generic fluconazole |
fluconzole |
|
|
|
|
|
|
$297,061 |
|
| Synagis
Tax refund |
Synagis |
Synagis is exempt from SC tax per Title 12 Chapter 36 of the SC
Sales and Use Tax Act |
|
|
|
|
|
$338,240 |
|
| Taxes
for AHFS classification 10:00 |
|
|
|
|
|
|
|
|
not yet finalized |
| Duragesic
generic |
Duragesic |
AB rated generic for Duragesic patches |
|
$50,000 |
none *340B brand price is less than generic price |
$50,000.00 |
Mar-05 |
$45,000 |
|
| Quarterly
submission of Novation Failure to Supply Reports |
various |
Manufacturers that have agreed to reimburse for medications that
were not supplied. These reports are
faxed quarterly |
|
|
|
|
Jan-05 |
$599 |
|
| Lorazepam/chlorazepate
Antitrust Litigation |
|
settlement check |
|
|
|
|
|
$532 |
|
| |
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|